Cargando…
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ pharmacologic features, detailed its mechanism of action, and summarized the existing guidelines and recommendations for HCQ...
Autores principales: | Dima, Alina, Jurcut, Ciprian, Chasset, François, Felten, Renaud, Arnaud, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848057/ https://www.ncbi.nlm.nih.gov/pubmed/35186126 http://dx.doi.org/10.1177/1759720X211073001 |
Ejemplares similares
-
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019) -
Prescription strategy of antimalarials in cutaneous and systemic
lupus erythematosus: an international survey
por: Petitdemange, Arthur, et al.
Publicado: (2021) -
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
por: Felten, Renaud, et al.
Publicado: (2021) -
Hydroxychloroquine ototoxicity in a patient with systemic lupus
erythematosus
por: Fernandes, Mariana Rita de Novaes, et al.
Publicado: (2018) -
Hydroxychloroquine-induced retinal toxicity in systemic lupus erythematosus
por: Piggott, Kisha D, et al.
Publicado: (2018)